Home
About
Capabilities
R&D
Investors
News
Careers
简
繁
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
Jun 29, 2026
2026 WOC | Mabwell Presents Clinical Results of Anti-VEGF Antibody 9MW0211 as Oral Presentation
➞
Jun 24, 2026
Mabwell Receives IND Clearance from NMPA for 9MW5211 for Multiple Sclerosis
➞
Jun 23, 2026
Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
➞
Jun 18, 2026
Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
➞
Jun 16, 2026
Mabwell's Subsidiary Myvision Enters Strategic Cooperation with VivaVision
➞
Jun 15, 2026
EHA 2026 | Mabwell Presents Latest Clinical Results of Novel Anti-TMPRSS6 Monoclonal Antibody 9MW3011
➞
Jun 12, 2026
Mabwell’s LILRB4/CD3 targeting TCE Bispecific Antibody 6MW5311 Receives FDA Clearance for Clinical Trial Application
➞
Jun 05, 2026
Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
➞
Jun 04, 2026
Mabwell’s Subsidiary Myvision Appears at Retina China 2026
➞
Jun 03, 2026
Highlights in Oral Presentation of Mabwell's 9MW2821 at 2026 ASCO
➞
1
2
3
4
Next